cisplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

234 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
BEAT-SC, jRCT2080224946: Tecentriq_SCLC(1L)_Bev_comb[]

Completed
3
330
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer
 
 
NCT00705029: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Recruiting
3
244
US
alpha-lipoic acid, placebo
University of Medicine and Dentistry New Jersey, M.D. Anderson Cancer Center, Jarrow Formulas Inc
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
01/09
 
SQUIRE, NCT00981058 / 2009-013838-25: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2015
More
Active, not recruiting
3
1093
Europe, Canada, US, RoW
Necitumumab, IMC-11F8, LY3012211, Gemcitabine, LY2334737, Cisplatin
Eli Lilly and Company, Parexel, PPD, Medidata Solutions, Laboratory Corporation of America, University of Colorado, Denver, Thermo Fisher Scientific FS, ICON Clinical Research, Pacific Biomarkers, Sysmex Inostics GmbH, Intertek
Non Small Cell Lung Cancer
06/13
06/24
OS2006, NCT00470223 / 2006-003377-27: Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Active, not recruiting
3
318
Europe
cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery
UNICANCER, Novartis, Chugai Pharmaceutical, National Cancer Institute, France, SFCE, Ligue contre le cancer, France
Sarcoma
12/15
12/26
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
KEYNOTE-189, NCT02578680 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/)

Checkmark From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Dec 2019 - Dec 2019: From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Checkmark Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Sep 2019 - Sep 2019: Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Checkmark Updated data in combination with Alimta for metastatic nonsquamous 1L NSCLC
More
Completed
3
616
NA
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
11/17
06/23
2017-002311-34: Phase 3 Study of Pembro with/without Epacadostat in 1L Urothelial Carcinoma Estudio de fase 3 de pembrolizumab con/sin epacadostat en el tratamiento de primera línea del carcinoma urotelial

Ongoing
3
650
Europe
pembrolizumab, Epacadostat, MK-3475, INCB024360, Solution for infusion, Tablet
Incyte Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Bladder cancer Cáncer de vejiga, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-669, NCT03358472 / 2017-001338-24: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (/ECHO-304)

Active, not recruiting
3
89
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Epacadostat, INCB024360, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Incyte Corporation, Merck Sharp & Dohme LLC
Head and Neck Cancer
07/18
12/24
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
Checkmark OS data from MYSTIC trial in 1L NSCLC
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/24
CRITICS, NCT00407186 / 2006-004130-32: Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer

Active, not recruiting
3
788
Europe
cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG
Gastric Cancer
12/18
12/25
KEYNOTE-048, NCT02358031 / 2014-003698-41: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/)

Checkmark Data from KEYNOTE-048 trial for SCCHN at ESMO 2020
Sep 2020 - Sep 2020: Data from KEYNOTE-048 trial for SCCHN at ESMO 2020
Checkmark KEYNOTE-048 trial at ASCO 2019
May 2019 - May 2019: KEYNOTE-048 trial at ASCO 2019
Checkmark KEYNOTE-048 trial for 1L SCCHN
More
Completed
3
882
NA
Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, Carboplatin, 5-FU, Cetuximab
Merck Sharp & Dohme LLC
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
02/19
07/23
2018-001811-59: This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Not yet recruiting
3
1050
Europe
durvalumab, MEDI4736, Concentrate for solution for infusion, Remicade 100mg powder for concentrate for solution for infusion, Celicept 250mg Capsules, Micofenolato Mofetile, Mycophenolate mofetil Sandoz 250 mg, Inflectra 100 mg powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder, Muscle Invasive Bladder Cancer (T2-T4a) in stage II and IIIA without lymph node involvement, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-189 Japan Extension study, NCT03950674 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Checkmark Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Checkmark Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Sep 2022 - Sep 2022: Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Checkmark From KEYNOTE-189 in 2L NSCLC
More
Completed
3
40
Japan
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
05/19
06/23
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
2018-004250-17: International Trial for Patients with High Risk Medulloblastoma

Ongoing
3
850
Europe
Thiotepa, Vincristine, Lomustine, Cyclophosphamide, Temozolomide, Carboplatin, Cisplatin, [Thiotepa], [VIncristina solfato], [Lomustine], [Ciclofosfamide], [Temozolomide], [Carboplatino], [Cisplatino], Powder for concentrate for solution for infusion, Solution for injection/infusion, Capsule, hard, Powder for solution for injection/infusion, Concentrate for solution for infusion, TEPADINA, Vincristine Sulphate 1 mg/ml Injection, Lomustine "medac", Cyclophosphamide, Temodal®, Carboplatin, Cisplatin
University of Birmingham, UNIVERSITY OF BIRMINGHAM, Cancer Research UK, , Barncancerfonden
Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-wingless-type (WNT) (Groups 3 and 4) medulloblastoma, with at least one additional high risk feature, Brain tumour, Diseases [C] - Cancer [C04]
 
 
2019-002784-10: Study in patients with untreated extensive-stage small cell lung cancer with carboplatin or cisplatin plus etoposide with Atezolizumab Estudio para pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado con carboplatino o cisplatino más etopósido con Atezolizumab

Ongoing
3
150
Europe
Atezolizumab, RO5541267/F03, Concentrate for solution for infusion, Tecentriq.
Roche Farma S.A. (Soc. Unipersonal), Roche Farma S.A. (Soc. Unipersonal)
First-line treatment for extensive-stage small cell lung cancer Primera línea de tratamiento en pacientes con Cáncer de pulmón microcítico en etapa avanzada, Untreated extensive-stage small cell lung cancer Cáncer de pulmón de célula pequeña en etapa avanzada no tratado, Diseases [C] - Cancer [C04]
 
 
DANUBE , NCT02516241 / 2015-001633-24: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Checkmark From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Checkmark From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Hourglass Mar 2020 - Jun 2020 : Regulatory submission in EU (based on DANUBE trial) for 1L bladder cancer in combination with tremelimumab
More
Active, not recruiting
3
1126
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
AstraZeneca
Urothelial Cancer
01/20
12/24
CASPIAN, NCT03043872 / 2016-001203-23: Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Sep 2021 - Sep 2021: From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Checkmark From CASPIAN trial in 1L SCLC at ESMO 2020
Sep 2020 - Sep 2020: From CASPIAN trial in 1L SCLC at ESMO 2020
Checkmark From CASPIAN trial in combination with tremelimumab for 1L extensive-stage SCLC at ASCO 2020
More
Active, not recruiting
3
987
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
01/20
12/24
2019-000944-82: Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable BTC

Not yet recruiting
3
1048
Europe
pembrolizumab, Keytruda (pembrolizumab, MK-3475), MK-3475, Solution for infusion, Keytruda (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder), Advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer). This study is for treatment naïve participants, Diseases [C] - Cancer [C04]
 
 
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
Orient-12, NCT03629925: Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Checkmark NMPA approved sNDA in combination with gemcitabine for locally advanced or metastatic sqNSCLC
Jun 2021 - Jun 2021: NMPA approved sNDA in combination with gemcitabine for locally advanced or metastatic sqNSCLC
Checkmark Data from trial for 1L squamous NSCLC
Sep 2020 - Sep 2020: Data from trial for 1L squamous NSCLC
Checkmark Data from orient-12 trial for advanced or recurrent squamous NSCLC at ESMO 2020
More
Completed
3
357
RoW
Sintilimab, IBI308, Gemcitabine, Cisplatin, Placebo, Carboplatin
Innovent Biologics (Suzhou) Co. Ltd.
Squamous NSCLC
03/20
09/21
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.

Not yet recruiting
3
1020
Europe
Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion
Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council
Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04]
 
 
2019-002463-10: A study of BLU-667 in patients with lung cancer

Not yet recruiting
3
250
Europe
Pralsetinib, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Pemetrexed, BLU-667, N/A, Capsule, Concentrate for solution for infusion, Powder for solution for infusion, Lyophilisate for solution for infusion, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Alimta
Blueprint Medicines Corporation, F. Hoffmann-La Roche Ltd, F. Hoffmann La-Roche Ltd, BLUEPRINT MEDICINES CORPORATION, Blueprint Medicines, F.Hoffmann-La Roche Ltd., F. Hoffmann La-Roche Ltd, F. Hoffmann-La Roche Ltd.
RET fusion-positive, Metastatic Non-Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-590, NCT03189719 / 2017-000958-19: First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/)

Completed
3
749
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Placebo, Cisplatin, 5-FU
Merck Sharp & Dohme LLC
Esophageal Neoplasms
07/20
07/23
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/24
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Checkmark From trial for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial for NSCLC at ESMO 2020
Checkmark From trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC
More
Completed
3
334
RoW
Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed, Cisplatin or Carboplatin,Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
10/20
04/23
ARIEL4, NCT02855944 / 2016-000816-14: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Checkmark Data from ARIEL4 trial for BRCA1/2-mutated ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from ARIEL4 trial for BRCA1/2-mutated ovarian cancer at ESMO 2022
Checkmark Subgroup analysis data from ARIEL4 trial for ovarian cancer at ASCO 2021
Jun 2021 - Jun 2021: Subgroup analysis data from ARIEL4 trial for ovarian cancer at ASCO 2021
Checkmark Data from ARIEL4 trial for advanced ovarian cancer
More
Completed
3
349
Europe, Canada, US, RoW
Chemotherapy, Cisplatin, carboplatin, carboplatin/paclitaxel, carboplatin/gemcitabine, paclitaxel, Rucaparib, CO-338, AG 14699, PF 01367338, Rubraca
zr Pharma & GmbH, Foundation Medicine
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
12/20
09/22
CheckMate 648, NCT03143153 / 2016-001514-20: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Checkmark Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from CheckMate 648 trial in combination with Yervoy for ESCC at ASCO-GI 2023
Checkmark Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
May 2022 - May 2022: Approved in combination with Yervoy for 1L ESCC based on Checkmate-648 trial
Checkmark Approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for 1L ESCC based on Checkmate-648 trial
More
Active, not recruiting
3
970
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558 (Nivolumab), Opdivo (Nivolumab), Ipilimumab, BMS-734016 (Ipilimumab), Yervoy (Ipilimumab), Cisplatin, Fluorouracil
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Various Advanced Cancer
01/21
01/25
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Checkmark Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Checkmark Full data presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2021
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
12/26
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Checkmark Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Jun 2022 - Jun 2022: Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Checkmark Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Jun 2022 - Jun 2022: Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Checkmark Presentation of data from RATIONALE 309 trial for 1L recurrent or metastatic nasopharyngeal cancer at ASCO plenary series 2022
More
Active, not recruiting
3
256
RoW
Tislelizumab, BGB-A317, Placebo, Gemcitabin, Cisplatin
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
03/21
06/25
2020-001001-22: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, unresctable ESCC

Not yet recruiting
3
600
Europe
Durvalumab, Cisplatin, capecitabine, 5-fluorouracil, MEDI4736, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Cisplatin NeoCorp® 1 mg/mL - concentrate for solution for infusion, Capecitabine (Capecitabin cell pharm® 150 mg and 500 mg film-coated tablets), 5-FU medac 50 mg/ml, solution for injection, Capecitabine Accord 150 mg and 500 mg film coated tablets, Cisplatin Teva® 1 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Benda-5 FU 50 mg/ml, solution for injection
AstraZeneca AB, AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Specific type of Esophageal cancer called "Esophageal Squamous Cell Carcinoma" (ESCC) that cannot be removed by surgery, Diseases [C] - Cancer [C04]
 
 
2019-004630-42: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Not yet recruiting
3
216
Europe
Futibatinib, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, TAS-120, Film-coated tablet, Concentrate for solution for infusion, Cisplatin 1 mg/mL Concentrate for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion
Taiho Oncology Inc, Taiho Oncology, Inc., TAIHO ONCOLOGY INC., Taiho Oncology Inc
Advanced solid tumors, Advanced solid tumors, Diseases [C] - Cancer [C04]
 
 
2021-000245-41: Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups. Trattamento con Olaparib oltre la progressione confrontato con chemioterapia a base di platino dopo citoriduzione secondaria in pazienti con recidiva da carcinoma ovarico. MITO 35b, studio di fase 3 randomizzato: un progetto dei Gruppi MITO-MANGO.

Ongoing
3
200
Europe
CARBOPLATINO, LYNPARZA, Cisplatino, Gemcitabina, Paclitaxel, Doxorubicina Liposomiale Pegilata, [CARBOPLATINO], [LYNPARZA], [Cisplatino], [Gemcitabina], [Paclitaxel], [Doxorubicina Liposomiale Pegilata], Concentrate for solution for infusion, Film-coated tablet, LYNPARZA - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE, LYNPARZA - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Diseases [C] - Cancer [C04]
 
 
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Not yet recruiting
3
204
Europe
Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04]
 
 
LEAP-011, NCT03898180 / 2018-003752-21: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ )

Checkmark From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Sep 2019 - Sep 2019: From LEAP-011 trial in combination with Lenvima for urothelial carcinoma at ESMO 2019
Active, not recruiting
3
487
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Placebo for lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Urothelial Carcinoma
07/21
07/24
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
263
RoW
Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
08/21
12/22
CANOPY-1, NCT03631199 / 2018-001547-32: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Hourglass Oct 2021 - Dec 2021 : From CANOPY-1 trial in combination with Keytruda for 1L NSCLC
Checkmark PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Dec 2021 - Dec 2021: PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Checkmark P3 CANOPY-1 trial in combination with canakinumab
Dec 2018 - Dec 2018: P3 CANOPY-1 trial in combination with canakinumab
Active, not recruiting
3
673
Europe, Canada, Japan, US, RoW
canakinumab, ACZ885, canakinumab matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
08/21
06/27
TOPAZ-1, NCT03875235 / 2018-004688-30: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer

Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Jul 2022 - Jul 2022: Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Jan 2022 - Jan 2022: Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Checkmark From P3 TOPAZ-1 trial for 1L BTC at ASCO-GI 2022
More
Active, not recruiting
3
810
Europe, Japan, US, RoW
Durvalumab, Placebo
AstraZeneca
Biliary Tract Neoplasms
08/21
03/25
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
ORIENT-15, NCT03748134: Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( )

Checkmark Data from ORIENT-15 study in advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from ORIENT-15 study in advanced or metastatic esophageal squamous cell cancer at ESMO 2021
Completed
3
746
Europe, US, RoW
Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo
Innovent Biologics (Suzhou) Co. Ltd., Fortrea
Esophageal Squamous Cell Carcinoma
09/21
07/23
2021-000830-33: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne La PIPAC (Pressurized intraperitoneal aerosol chemotherapy) nella terapia multimodale per pazienti con metastasi peritoneale limitata da cancro gastrico: studio sperimentale multicentrico randomizzato di fase III. PIPAC_VEROne

Not yet recruiting
3
98
Europe
Oxaliplatino, 5-Fluorouracile, Cisplatino, Doxorubicina, Acido folinico, [Oxaliplatino], [Fluorouracile], [Cisplatino], [Doxorubicina], [Calcio levofolinato], Concentrate for solution for injection/infusion, Solution for injection/infusion, Powder for solution for injection/infusion
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, Azienda Ospedaliera Universitaria Integrata Verona
Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Diseases [C] - Digestive System Diseases [C06]
 
 
JAVELIN Lung 100, NCT02576574 / 2015-001537-24: Avelumab in First-line NSCLC

Checkmark Data from JAVELIN Lung 100 trial for 1L NSCLC
Feb 2022 - Feb 2022: Data from JAVELIN Lung 100 trial for 1L NSCLC
Checkmark Avelumab program rollover study in solid tumor
Jan 2019 - Jan 2019: Avelumab program rollover study in solid tumor
Checkmark Registration study for 1L NSCLC
More
Completed
3
1214
Europe, Canada, Japan, US, RoW
Avelumab, Anti-PD-L1, MSB0010718C, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
First Line Non-Small Cell Lung Cancer
12/21
01/24
R000007398: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)

Completed
3
230
Japan
gefitinib - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Suita Tokushukai Hospital, AstraZeneca K.K.
Resected pathological stage II or III non-small cell lung cancer with mutated EGFR
 
 
CALLA, NCT03830866 / 2018-002872-42: Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer

Checkmark Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Sep 2022 - Sep 2022: Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Checkmark From CALLA trial for advanced cervical cancer
Mar 2022 - Mar 2022: From CALLA trial for advanced cervical cancer
Completed
3
770
Europe, Japan, US, RoW
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
AstraZeneca
Locally Advanced Cervical Cancer
01/22
07/23
RATIONALE 306, NCT03783442 / 2018-000587-28: A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Checkmark Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Dec 2022 - Dec 2022: Data from RATIONALE 306 trial for 1L locally advanced metastatic esophageal squamous cell carcinoma at ASCO-GI 2023
Checkmark Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Jun 2022 - Jun 2022: Presentation of data from RATIONALE 306 trial for 1L locally advanced metastatic ESCC at ESMO GI 2022
Checkmark Data from RATIONALE 309 trial for 1L locally advanced, recurrent or metastatic ESCC
More
Active, not recruiting
3
649
Europe, Japan, US, RoW
Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo
BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
02/22
08/24
2021-003185-12: Pembrolizumab vs Platinum Doublet Chemotherapy in Participants with dMMR Advanced or Recurrent Endometrial Carcinoma in the First-line Setting Pembrolizumab frente a la quimioterapia doble con derivados del platino en participantes con carcinoma endometrial avanzado o recurrente con defectos en la reparación de errores de emparejamiento (dMMR) en primera línea.

Ongoing
3
350
Europe
Solution for infusion, Concentrate for solution for infusion, KEYTRUDA®, Carboplatin Bendalis, Carboplatin Kabi, Cisplatin Teva, Paclitaxel EVER Pharma, Docetaxel EVER Valinject, Docetaxel AqVida, Docetaxel cell pharm, Docetaxel, Cisplatin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
First-line treatment of participants with dMMR advanced or recurrent EC Estudio de fase 3 de pembrolizumab frente a quimioterapia en el carcinoma endometrial avanzado o recurrente con dMMR., Stage III or IV or recurrent endometrial carcinoma (EC), centrally confirmed as dMMR, with no prior systemic therapy for advanced EC, except radiosensitizing chemotherapy or hormonal therapy. Carcinoma endometrial (CE) en estadio III o IV o recidivante, confirmado con dMMR, sin terapia sistémica previa para el CE avanzado, excepto quimioterapia radiosensibilizante o terapia hormonal., Diseases [C] - Cancer [C04]
 
 
KEYNOTE-412, NCT03040999 / 2016-003934-25: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/)

Checkmark Presentation of data from KEYNOTE-412 trial for locally advanced SCCHN at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-412 trial for locally advanced SCCHN at ESMO 2022
Checkmark Results from KEYNOTE-412 trial for unresected locally advanced HNSCC
Jul 2022 - Jul 2022: Results from KEYNOTE-412 trial for unresected locally advanced HNSCC
Active, not recruiting
3
804
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, Placebo, Cisplatin, Platinol®, Platinol®-AQ, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
Merck Sharp & Dohme LLC
Head and Neck Neoplasms
05/22
08/24
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Not yet recruiting
3
290
RoW
ENDOSTAR，cisplatin, Placebo , cisplatin
Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
06/22
10/23
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico

Not yet recruiting
3
324
Europe
Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin

Not yet recruiting
3
830
Europe
Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04]
 
 
2021-005879-40: Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Estudio en fase III de patritumab deruxtecán frente a quimioterapia basada en platino en el CPNM metastásico o localmente avanzado con EGFRm tras el fracaso del tratamiento con ITC del EGFR

Not yet recruiting
3
560
Europe
Patritumab Deruxtecan, Pemetrexed, Cisplatin, Carboplatin, U3-1402, NA, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Vitamin B12 1000 µg, Folic Acid, Cisplatin, carboplatin, pemetrexed
Daiichi Sankyo, Inc., DAIICHI SANKYO INC., DAIICHI SANKYO. INC., Daiichi Sankyo, Inc.
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm), Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM), Diseases [C] - Cancer [C04]
 
 
IMvigor130, NCT02807636 / 2016-000250-35: Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Checkmark From IMvigor130 trial in 1L urothelial cancer
Sep 2019 - Sep 2019: From IMvigor130 trial in 1L urothelial cancer
Completed
3
1213
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Carboplatin, Gemcitabine, Placebo, Cisplatin
Hoffmann-La Roche
Urothelial Carcinoma
08/22
02/24
KEYNOTE-826, NCT03635567 / 2018-001440-53: Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/)

Checkmark Full data from KEYNOTE-826 study for Keytruda + chemotherapy with/without bevacizumab for recurrent/metastatic 1L cervical cancer at ESMO 2021
Sep 2021 - Sep 2021: Full data from KEYNOTE-826 study for Keytruda + chemotherapy with/without bevacizumab for recurrent/metastatic 1L cervical cancer at ESMO 2021
Checkmark From KEYNOTE-826 trial in combination with Avastin and chemotherapy for 1L cervical cancer
Jun 2021 - Jun 2021: From KEYNOTE-826 trial in combination with Avastin and chemotherapy for 1L cervical cancer
Completed
3
617
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Cisplatin, PLATINOL®, Carboplatin, PARAPLATIN®, Bevacizumab, AVASTIN®, Placebo to pembrolizumab, Normal Saline or Dextrose solution
Merck Sharp & Dohme LLC
Cervical Cancer
10/22
06/24
KEYNOTE-859, NCT03675737 / 2018-001757-27: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/)

Checkmark Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Nov 2022 - Nov 2022: Topline data from KEYNOTE-859 trial for HER2- 1L advanced gastric or gastroesophageal junction adenocarcinoma
Active, not recruiting
3
1579
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, PLATINOL®, 5-fluorouracil, ADRUCIL®, 5FU, oxaliplatin, ELOXATIN®, capecitabine, XELODA®, Placebo for Pembrolizumab
Merck Sharp & Dohme LLC
Stomach Neoplasms
10/22
03/25
PEARL, NCT03003962 / 2018-001375-21: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Checkmark Data from PEARL trial for Stage IV (metastatic) NSCLC
Dec 2022 - Dec 2022: Data from PEARL trial for Stage IV (metastatic) NSCLC
Checkmark From PEARL trial for 1L NSCLC
Oct 2021 - Oct 2021: From PEARL trial for 1L NSCLC
Active, not recruiting
3
669
Europe, US, RoW
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
10/22
06/26
2022-001144-18: A clinical study comparing efficacy and safety of xevinapant against placebo when given with radiotherapy in participants who had their locally advanced squamous cell carcinoma of the head and neck removed by surgery, are at high risk for the cancer to return and who cannot be treated with high-dose cisplatin.

Ongoing
3
700
RoW
Xevinapant, MSC2735845A, Oral solution
Merck Healthcare KGaA, Merck Healthcare KGaA
Resected squamous cell carcinoma of the head and neck, Resected squamous cell carcinoma of the head and neck, Diseases [C] - Cancer [C04]
 
 
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
NCT04426955: Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Active, not recruiting
3
396
RoW
Camrelizumab, SHR-1210, Paclitaxel, Cisplatin, Placebo, Radiation
Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer
12/22
12/23
KEYNOTE-966, NCT04003636: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/)

Checkmark Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Jan 2023 - Jan 2023: Interim results from KEYNOTE-966 trial in combination chemotherapy for patients with advanced or unresectable 1L BTC.
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
KEYNOTE-966 China Extension study, NCT04924062: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Active, not recruiting
3
158
RoW
Pembrolizumab, MK-3475, Gemcitabine, Gemzar, Cisplatin, Platinol®, Platinol®-AQ, Placebo
Merck Sharp & Dohme LLC
Biliary Tract Carcinoma
12/22
11/24
KEYNOTE-789, NCT03515837 / 2017-004188-11: Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/)

Completed
3
492
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, pemetrexed, carboplatin, cisplatin, saline solution, Normal saline solution
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
01/23
10/23
NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated
3
36
RoW
Sintilimab, Tyvyt, IBI308, Ramucirumab, LY3009806, IMC-1121B, Cyramza, Cisplatin, 5-fluorouracil, Oxaliplatin, Capecitabine
Innovent Biologics (Suzhou) Co. Ltd.
Gastric Adenocarcinoma
02/23
02/23
SKYSCRAPER-08, NCT04540211: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Jan 2023 - Dec 2023: Data from SKYSCRAPER-08 trial in combination with tiragolumab for metastatic esophageal carcinoma
Active, not recruiting
3
461
RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Paclitaxel, Cisplatin, Atezolizumab Matching Placebo, Tiragolumab Matching Placebo
Hoffmann-La Roche
Esophageal Cancer
02/23
08/25
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Hourglass Jan 2023 - Dec 2023 : Submission in US for 1L gastric cancer
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
Checkmark Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Jan 2022 - Jan 2022: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
Active, not recruiting
3
997
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU
BeiGene
Gastric, or Gastroesophageal Junction Adenocarcinoma
02/23
12/24
CONTINUUM, NCT03700476: Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Active, not recruiting
3
425
RoW
Sintilimab, IBI308, PD-1 antibody, Gemcitabine, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd.
Nasopharyngeal Neoplasms
02/23
01/25
PROOF 301, NCT03773302 / 2018-004004-19: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Checkmark BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Oct 2022 - Oct 2022: BridgeBio terminated ongoing phase 3 clinical trial for treating 1L cholangiocarcinoma as a result of withdrawal of NDA
Terminated
3
48
Europe, Canada, US, RoW
BGJ398, Infigratinib, Gemcitabine, Cisplatin
QED Therapeutics, Inc., Helsinn Healthcare SA
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
03/23
03/23
Oriental, NCT04449861: Durvalumab Plus Chemotherapy in ES-SCLC

Completed
3
166
RoW
Durvalumab plus chemotherapy
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
03/23
03/23
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - PDUFA date for FDA approval in adults with locally advanced/metastatic EGFRm NSCLC (based on FLAURA2 trial)
Jan 2022 - Dec 2023: Data from FLAURA2 trial in combination with carboplatin or pemetrexed/cisplatin for 1L EGFRm NSCLC
Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
AstraZeneca
Non-Small Cell Lung Cancer
04/23
06/26
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting
3
531
Europe, Japan, US, RoW
Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Non-Small Cell Lung Cancer
04/23
10/26
RATIONALE-312, NCT04005716: Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Completed
3
457
RoW
Tislelizumab, Carboplatin /Cisplatin, Etoposide, Carboplatin / Cisplatin, Etoposide
BeiGene
Small Cell Lung Cancer
04/23
12/23
ASTRUM-007, NCT03958890: A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Active, not recruiting
3
489
RoW
HLX10 100 mg in 10 ml Injection, Placebos
Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma
04/23
12/23
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Nov 2021 - Nov 2021: Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Checkmark Data from first interim analysis in combination with Byvasda and chemo in EGFR mutated nonsquamous NSCLC
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
261
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
05/23
06/26
PIVOT IO 009, NCT04209114 / 2018-002676-40: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Calendar Jan 2023 - Dec 2024: From trial in combination with nivolumab for first-line muscle-invasive bladder cancer
Completed
3
114
Europe, Canada, US, RoW
Nivolumab, Opdivo, BMS-936558, Radical cystectomy (RC), Bempegaldesleukin, BMS-986321, NKTR-214, Bempeg
Bristol-Myers Squibb, Nektar Therapeutics
Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
06/23
06/23
NCT06212752: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Active, not recruiting
3
378
Japan
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
CANTABRICO, NCT04712903: Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Completed
3
101
Europe
Durvalumab, Cisplatin, Etoposide, Carboplatin
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
06/23
06/23
2022-002877-27: A clinical trial testing the hormonal drug letrozole alone or in addition to the usual chemotherapy treatment (paclitaxel and carboplatin) in low-grade serous ovarian or peritoneal cancer.

Not yet recruiting
3
450
Europe
Letrozole, Paclitaxel, Carboplatin, Anastrozole, Exemestane, Cisplatin, Docetaxel, Paclitaxel formulated as albumin bound nanoparticles, Film-coated tablet, Concentrate for solution for infusion, Powder for dispersion for infusion, Femara®, Abraxane
Cancer Trials Ireland, NRG Oncology, Friends of Cancer Trials Ireland, Irish Cancer Society
Primary low-grade serous carcinoma of the ovary or peritoneum., A specific type of cancer called low-grade serous carcinoma of the ovary or peritoneum., Diseases [C] - Cancer [C04]
 
 
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
KEYNOTE-A39, NCT04223856 / 2019-004542-15: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Calendar Apr 2024 - Dec 2025: Accelerated approval in US in combination with Keytruda for 1L/metastatic urothelial cancer (based on EV-302 trial)
Calendar Apr 2024 - Mar 2025: Regulatory submission in JP for 1L metastatic urothelial cancer
Calendar Apr 2024 - Dec 2024: Accelerated approval in US in combination with Padcev for 1L/metastatic urothelial cancer (based on EV-302 trial)
Jan 2023 - Dec 2023: Topline data from EV-302 trial in combination with Keytruda for 1L urothelial cancer
Hourglass Jul 2022 - Dec 2022 : Completion of enrollment of EV-302 trial in combination with Keytruda for urothelial cancer
More
Recruiting
3
990
Europe, Canada, Japan, US, RoW
Enfortumab vedotin, ASG-22CE, ASG-22ME, PADCEV, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Gemcitabine
Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC, Seagen Inc.
Urothelial Cancer
08/23
09/27
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/)

Checkmark Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Sep 2020 - Sep 2020: Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Checkmark Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
Jul 2020 - Jul 2020: Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
Checkmark Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
More
Active, not recruiting
3
761
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Active, not recruiting
3
201
RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
ORIENT-99, NCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Recruiting
3
500
RoW
Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer
09/26
10/28
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
PACIFIC2, NCT03519971 / 2017-004397-34: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Jul 2023 - Dec 2023: Acceptance of regulatory submission for CRT+ NSCLC (based on PACIFIC-2 trial)
Jul 2023 - Dec 2023: Data from PACIFIC-2 trial for advanced NSCLC
Hourglass Jan 2021 - Dec 2021 : Regulatory submission for advanced stage 3 NSCLC (based on PACIFIC-2 trial)
Active, not recruiting
3
328
Europe, Japan, RoW
Durvalumab, MEDI4736, Placebo, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation
AstraZeneca
Non-Small Cell Lung Cancer
09/23
03/25
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
CA017-078, NCT03661320 / 2017-004692-31: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Calendar Jan 2024 - Dec 2024: Data from CA 017-078 trial in combination with chemotherapy for muscle invasive urothelial cancer
Active, not recruiting
3
861
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS-936558, Gemcitabine, Chemotherapy, Cisplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer
04/25
12/27
DOMAJOR, NCT03912389 / 2018-004791-36: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Recruiting
3
292
Europe, RoW
BCD-100, Pemetrexed, Cisplatin (or carboplatin), Placebo
Biocad
Non-Squamous Non-Small Cell Neoplasm of Lung
12/23
12/23
FOENIX-CCA3, NCT04093362 / 2019-004630-42: Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Active, not recruiting
3
216
Europe, Japan, US, RoW
TAS-120, Futibatinib, Cisplatin/Gemcitabine
Taiho Oncology, Inc., Taiho Oncology Inc
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
06/24
06/24
CheckMate 77T, NCT04025879 / 2019-000262-38: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data readout CheckMate-77T trial for peri adjuvant NSCLC
Hourglass Nov 2023 - Mar 2024 : H2 FY’23 - Submission in Japan for neoadjuvant/adjuvant NSCLC based on CheckMate-77T trial
Active, not recruiting
3
482
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS936558, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
07/23
09/24
KEYNOTE 811, NCT03615326 / 2018-000224-34: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Checkmark From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Jun 2021 - Jun 2021: From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
Active, not recruiting
3
738
Europe, Japan, US, RoW
Pembrolizumab, Keytruda®, MK-3475, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab, Herceptin®
Merck Sharp & Dohme LLC
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
03/24
12/24
NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
298
Canada, US, RoW
Penpulimab, cisplatin, gemcitabine, placebo
Akeso
Nasopharyngeal Carcinoma
02/25
09/26
GEMSTONE-304, NCT04187352: A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Checkmark Topline data from the GEMSTONE-304 trial in 1L metastatic esophageal squamous cell carcinoma
Jan 2023 - Jan 2023: Topline data from the GEMSTONE-304 trial in 1L metastatic esophageal squamous cell carcinoma
Completed
3
540
RoW
CS1001+ Fluorouracil+Cisplatin, Placebo+ Fluorouracil+Cisplatin
CStone Pharmaceuticals
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
10/22
10/22
RATIONALE-310, NCT03967977: Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Recruiting
3
420
RoW
Tislelizumab, BGB-A317, Placebo, Cisplatin, Gemcitabine Hydrochloride, Carboplatin
BeiGene
Urothelial Carcinoma
06/27
06/27
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Hourglass Jul 2023 - Dec 2023 : Data from NILE trial in combination with tremelimumab for 1L bladder cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission (based on NILE trial) in combination with Imfinzi for urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission based on NILE trial in EU in combination with tremelimumab for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU in combination with Imfinzi for 1L urothelial cancer (based on NILE trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan in combination with tremelimumab for 1L urothelial cancer based on NILE trial
More
Active, not recruiting
3
1244
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
08/24
06/25
Beamion LUNG-2, NCT06151574: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting
3
270
Europe, Japan, US, RoW
zongertinib, BI 1810631, pembrolizumab, Keytruda®, cisplatin, carboplatin, pemetrexed
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
03/27
05/28
KEYNOTE-671, NCT03425643 / 2017-001832-21: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/)

Calendar Jan 2024 - Dec 2024: From KEYNOTE-0671 trial for resectable stage IIb or IIIa NSCLC
Hourglass Sep 2019 - Oct 2019 : Preliminary data from trial for advanced solid tumors and genomic instability at ESMO 2019
Active, not recruiting
3
797
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Placebo, Cisplatin, PLATINOL®, Gemcitabine, GEMZAR®, Pemetrexed, Alimta®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/23
06/26
 

Download Options